275 related articles for article (PubMed ID: 18560996)
1. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
Okumu A; DiMaso M; Löbenberg R
Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996
[TBL] [Abstract][Full Text] [Related]
2. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
3. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
Okumu A; DiMaso M; Löbenberg R
Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
[TBL] [Abstract][Full Text] [Related]
4. Simulation of in vitro dissolution behavior using DDDPlus™.
Almukainzi M; Okumu A; Wei H; Löbenberg R
AAPS PharmSciTech; 2015 Feb; 16(1):217-21. PubMed ID: 25409918
[TBL] [Abstract][Full Text] [Related]
5. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
[TBL] [Abstract][Full Text] [Related]
7. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
[TBL] [Abstract][Full Text] [Related]
8. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
Al-Gousous J; Amidon GL; Langguth P
Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
[TBL] [Abstract][Full Text] [Related]
9. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
Fuchs A; Leigh M; Kloefer B; Dressman JB
Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
[TBL] [Abstract][Full Text] [Related]
10. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
Guimarães M; Somville P; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
[TBL] [Abstract][Full Text] [Related]
11. One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products.
Prieto-Escolar M; Torrado JJ; Álvarez C; Ruiz-Picazo A; Simón-Vázquez M; Govantes C; Frias J; García-Arieta A; Gonzalez-Alvarez I; Bermejo M
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34064700
[TBL] [Abstract][Full Text] [Related]
12. Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
Nurhikmah W; Sumirtapura YC; Pamudji JS
Sci Pharm; 2016; 84(1):181-90. PubMed ID: 27110508
[TBL] [Abstract][Full Text] [Related]
13. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide.
Löbenberg R; Krämer J; Shah VP; Amidon GL; Dressman JB
Pharm Res; 2000 Apr; 17(4):439-44. PubMed ID: 10870988
[TBL] [Abstract][Full Text] [Related]
14. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: Case examples glibenclamide and dipyridamole.
Klumpp L; Dressman J
Eur J Pharm Sci; 2020 Aug; 151():105380. PubMed ID: 32442630
[TBL] [Abstract][Full Text] [Related]
17.
Silva TMD; Honorio TDS; Chaves MHDC; Duque MD; Cabral LM; Patricio BFC; Rocha HVA
Drug Dev Ind Pharm; 2021 Aug; 47(8):1342-1352. PubMed ID: 34622730
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
[TBL] [Abstract][Full Text] [Related]
19. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
Radwan A; Jayyousi R; Shraim N; Zaid AN
Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
